ARTL · Artelo Biosciences Inc. Common Stock
View on chartInsiders & Stakes
| Gorgas Gregory D. Pres, CEO, CFO, Treas & Secr | ▲ Buy | Open Market | 2,400 Shares held | 8/12/2022 | View profile |
Transaction History
| Gorgas Gregory D. | ▲ Buy | Open Market | 1,200 | $5K | 8/12/2022 |
| Gorgas Gregory D. | ▲ Buy | Open Market | 1,200 | $5K | 8/11/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
ARTL Selected for First Company Presentation at BIO‑Europe 2026
Artelo Biosciences has been chosen to present at BIO‑Europe 2026. The company will discuss clinical progress and the potential of its FABP5 inhibitor platform. This event highlights growing interest in the drug candidate and may increase visibility among researchers and investors. The presentation is a milestone in the company's development timeline.
ARTL Selected for First Company Presentation at BIO‑Europe 2026. Artelo Biosciences has been chosen to present at BIO‑Europe 2026. The company will discuss clinical progress and the potential of its FABP5 inhibitor platform. This event highlights growing interest in the drug candidate and may increase visibility among researchers and investors. The presentation is a milestone in the company's development timeline.